Related Experiment Video
Updated: Mar 3, 2026

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
Published on: March 13, 2013
Repressing CD147 is a novel therapeutic strategy for malignant melanoma
Xing Hu1,2, Juan Su1,2, Youyou Zhou2
1Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Abstract:
CD147/basigin, a transmembrane protein, is a member of the immunoglobulin super family. Accumulating evidence has revealed the role of CD147 in the development and progression of various cancers, including malignant melanoma (MM). MM is a malignancy of pigment-producing cells that causes the greatest number of skin cancer-related deaths worldwide. CD147 is overexpressed in MM and plays an important role in cell viability, apoptosis, proliferation, invasion, and metastasis, probably by mediating vascular endothelial growth factor (VEGF) production, glycolysis, and multi-drug resistance (MDR). As a matrix metalloproteinase (MMP) inducer, CD147 could also promote surrounding fibroblasts to secrete abundant MMPs to further stimulate tumor cell invasion. Targeting CD147 has been shown to suppress MM in vitro and in vivo, highlighting the therapeutic potential of CD147 silencing in MM treatment. In this review article, we discuss CD147 and its biological roles, regulatory mechanisms, and potential application as a molecular target for MM.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Abnormal Proliferation
Inhibition of Cdk Activity

